ANDA 219759, held by Aurobindo Pharma Ltd. Lidocaine Hydrochloride.
As of Nov 16, 2026, ANDA 219759 (Lidocaine Hydrochloride), held by Aurobindo Pharma Ltd, was first approved by FDA on Jul 29, 2025, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE: Lidocaine Hydrochloride Oral Topical Solution, USP 2% (Viscous) is indicated for the production of topical anesthesia of irritated or inflamed mucous membranes of the mouth and pharynx. It is also useful for reducing gagging during the taking of X-ray pictures and dental impressions.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 29, 2025 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Lidocaine Hydrochloride2% · solution;oral | Lidocaine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters